A recent longitudinal study shows that differences in cortical thickness may appear at least seven years before individuals cross an amyloid PET scan threshold.
In a study recently published in Nature Neuroscience by researchers James M. Roe and Yunpeng Wang of the University of Oslo, analysis of longitudinal MRI data revealed that differences in cortical thickness can be detected at least seven years before individuals cross the threshold for high amyloid plaque levels.
The study, which carries the reported DOI 10.1038/s41593-026-02363-4, analyzed data drawn from three separate studies of cognitive aging. To understand the timeline of structural changes in the brain, the researchers reviewed a substantial dataset over an extended period. The analysis included 4,570 MRI scans taken from 1,051 people. Within this broader group, 691 participants also had amyloid-beta PET scans available for review.
By combining the MRI and PET data, the research team could compare changes in physical brain structure against the accumulation of amyloid over time. The researchers focused heavily on the participants who provided PET data. Among those individuals, 77 people who were initially below the study’s amyloid threshold later crossed into the high, PET-positive range. Another 412 participants remained below that threshold across all their available scans.
The research team compared the MRI-measured cortical thickness in the years before participants’ first positive PET scan with the scans from the people who remained PET-negative. This backward-looking approach allowed the team to look for early structural differences that might precede the detectable plaque buildup. The findings revealed a distinct physical pattern among the participants who eventually showed high amyloid levels. Participants who later crossed the amyloid threshold had thicker cortices than those who remained below the threshold.
They also demonstrated slower age-related cortical thinning. According to Science News, this finding represents a difference of a few hundredths of a millimeter in cortical thickness. These differences were especially prominent in the frontal regions of the brain, and they were detectable at least seven years before a participant's first positive PET scan.
The traditional understanding of brain aging often assumes a straightforward biological sequence. In many models, amyloid plaque accumulation becomes detectable first, and structural changes follow afterward. The PsyPost account of the study notes that this new finding runs directly against that simple sequence. Because participants who later became PET-positive showed greater thickness and slower thinning years beforehand, scientists must reconsider the exact order of these biological events.
For older adults researching brain aging and neuroplasticity, this timing shifts the focus toward much earlier stages of structural change. While the timeline difference is notable, the study does not establish exactly why the MRI-measured thickness was greater in that specific group. The researchers proposed several possible reasons for the early thickness difference, but the actual cause remains completely uncertain. The PsyPost account discusses possible explanations such as early inflammation within the brain tissue.
It also mentions changes in supporting brain cells as another potential biological cause. The research team presents these ideas solely as possibilities rather than confirmed mechanisms. These findings provide valuable new data points for medical researchers mapping the aging process, but they do not change the immediate reality for patients today. The results specifically document the timing of cortical structure differences relative to PET amyloid positivity.
They do not introduce a new clinical test for everyday medical care. The study simply adds a complex new layer to ongoing research regarding early biological markers without altering daily health routines.
Interpreting medical research requires careful attention to what a specific study actually measures. The researchers classified people entirely by whether their amyloid PET scan crossed a predetermined threshold. This outcome is strictly a biological measurement of amyloid PET status. It is not the same thing as a clinical diagnosis of Alzheimer’s disease.
The study does not show that these participants had Alzheimer’s disease, developed symptoms of the disease, or would necessarily go on to develop dementia. The study reports a broad group-level difference, which Science News emphasizes is not an individual diagnosis tool. The PsyPost account does not report numerical effect sizes, confidence intervals, or p-values for the data. The size and individual-level predictive accuracy of the finding cannot be assessed from that account.
There is no validated cutoff or evidence that measuring one person’s cortical thickness can determine if they will ever become amyloid-positive. The observed MRI pattern cannot reliably predict individual health outcomes. The timeline of the findings also carries specific observational limits. Participants took PET scans at established intervals rather than having continuous monitoring.
The first positive scan marks the date when high amyloid was observed by researchers, which does not necessarily represent the precise biological moment the threshold was crossed. Because this timeline is estimated based on scan intervals, the seven-year mark represents a broad observational window rather than a strict biological schedule. Finally, the participants included in this research may not reflect the general population. The findings come strictly from cognitively healthy older adults.
The account notes that people who volunteer for long-term aging research may be healthier or higher-performing than the broader population. Those looking for practical lifestyle and brain resilience guidance should remember that this study is an observational research update, not a mandate for new health screenings.
For older adults wondering if they should seek out new brain scans based on this research, current clinical guidelines remain absolutely firm. PCORI reports that clinical practice guidelines do not recommend routine blood-based biomarker testing for detecting early Alzheimer’s pathology in people without symptoms. The new MRI study does not challenge or alter this guidance. It does not show that an asymptomatic person should seek an MRI or an amyloid PET test.
A BrightFocus interview likewise reports that clinicians generally do not recommend biomarker testing for cognitively unimpaired people at this time. This advice covers blood testing, spinal-fluid analysis, and PET testing alike. The established medical consensus holds that routine screening for asymptomatic individuals offers no current clinical benefit. The new findings are valuable for researchers working in laboratories, but they are not intended to change how independent adults approach their routine healthcare visits.
The study from the University of Oslo provides a valuable look at early structural differences in the aging brain. The data suggests that brain aging and plaque biology do not follow a simple timeline where amyloid appears first and structural changes always follow. Instead, early differences in cortical thickness may precede detectable plaque buildup by several years. This revelation complicates our ongoing understanding of neural changes over time, proving that the aging brain remains a complex subject for scientific study.
This research does not provide a personal prediction tool or a reason for cognitively healthy adults to pursue new screening methods. The findings remain a group-level observation of biological markers, not a diagnostic breakthrough for memory, attention, or day-to-day function. For adults focused on maintaining their memory and focus, the established medical advice remains exactly the same. Staying informed about cognitive research requires recognizing the critical difference between biological observations and practical medical guidelines.
Interpreting early structural brain scans requires separating group-level biological observations from actionable medical advice for the general public. Difficulty separating established evidence from early or exaggerated health claims can make reading the latest research stressful, but FitBrainLab clarifies these complex neuroimaging findings so you can focus on sensible routines for your cognitive health.
Follow FitBrainLab for research-led insights on memory, focus, brain aging, nutrition and mental fitness after 60. Stay connected for new articles, practical guidance and ideas for a sharper, more engaged life.
Build habits that support memory, focus and a curious, connected life.
Read the Blog
